НАРУШЕНИЯ ГЕМОСТАЗА ПРИ ЗАБОЛЕВАНИЯХ ПЕЧЕНИ
Аннотация
Печень играет ключевую роль в первичном и вторичном гемостазе, являясь местом синтеза всех факторов свертывания и их ингибиторов. Заболевания печени приводят к сложным изменениям в гемостазе, при этом сохраняется баланс между свертывающей и противосвертывающей системами, но со сниженным ре- зервом. Все больше накапливается данных о том, что тромбоз воротной и печеночных вен лежит в основе прогрессирования заболевания у пациентов с циррозом и усугубляет нарушения гемостаза. Эти наруше- ния гемостаза не всегда ведут к спонтанным кровотечениям, которые возникают только при наличии до- полнительных факторов, например инфекции. Обычно терапия расстройств коагуляции при заболеваниях печени требуется во время кровотечения или перед выполнением инвазивных процедур. У пациентов с заболеваниями печени в их конечной стадии трансплантация является единственным возможным методом лечения, который способен восстановить нормальный гемостаз и скорригировать генетические дефекты свертывания. Во время трансплантации печени кровотечения обусловлены сопутствующей гипокоагуля- цией, развитостью коллатеральной венозной сети вследствие портальной гипертензии и усилением актив- ности фибринолиза.
Об авторах
А. Ф. МиновБеларусь
А. М. Дзядзько
Беларусь
О. О. Руммо
Беларусь
Список литературы
1. Agarwal S., Joyner K.A.Jr., Swaim M.W. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease // Am. J. Gastroenterol. 2000. Vol. 95. P. 3218– 3224.
2. Albornoz L. et al. Von Willebrand factor could be an in- dex of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide le- vels // J. Hepatol. 1999. Vol. 30. P. 451–455.
3. Ben-Ari Z., Osman E., Hutton R.A., Burroughs A.K. Dis- seminated intravascular coagulation in liver cirrhosis: fact or fiction? // Am. J. Gastroenterol. 1999. Vol. 94. P. 2977–2982.
4. Bhattacharyya M. et al. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India // Am. J. Clin. Pathol. 2004. Vol. 121. P. 844–847.
5. Bismuth H. et al. Orthotopic liver transplantation in ful- minant and subfulminant hepatitis. The Paul Brousse ex- perience // Ann. Surg. 1995. Vol. 222. P. 109–119.
6. Bosch J. et al. Recombinant factor VIIa for upper gas- trointestinal bleeding in patients with cirrhosis: a ran- domized, double-blind trial // Gastroenterology. 2004. Vol. 127. P. 1123–1130.
7. Burroughs A.K. et al. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study // J. Hepatol. 2002. Vol. 37. P. 463–470.
8. Burroughs A.K. et al. Anticoagulation after liver trans- plantation: a retrospective audit and case-control study // Blood Coagul Fibrinolysis. 2009. Vol. 8 (20). P. 615– 618.
9. Carmassi F., Morale M., De Negri F., Carrai M. Mo- dulation of hemostatic balance with antithrombin III re- placement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis // J. Mol. Med. 1995. Vol. 73. P. 89–93.
10. Carr J.M. Disseminated intravascular coagulation in cir- rhosis // Hepatology. 1989. Vol. 10. P. 103–110.
11. Cerutti E. et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation // Liver. Transpl. 2004. Vol. 10. P. 289–294.
12. Clavien P.A. et al. Definition and classification of nega- tive outcomes in solid organ transplantation. Applica- tion in liver transplantation // Ann. Surg. 1994. Vol. 220. P. 109–120.
13. Dalmau A. et al. The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a com- parative study // Liver. Transpl. 2004. Vol. 10. P. 279– 284.
14. Ejlersen E. et al. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand // J. Gastroenterol. 2001. Vol. 36. P. 1081–1085.
15. Escolar G. et al. Evaluation of acquired platelet dysfunc- tions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation // Haematologica. 1999. Vol. 84. P. 614–619.
16. Espiritu J.D. Pulmonary embolism in a patient with co- agulopathy from end-stage liver disease // Chest. 2000. Vol. 117. P. 924–925.
17. Everson G.T. A hepatologist’s perspective on the ma- nagement of coagulation disorders before liver transplan- tation // Liver. Transpl. Surg. 1997. Vol. 3. P. 646–652.
18. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation // Dig. Dis. Sci. 1981. Vol. 26. P. 388–393.
19. Franchis R. et al. Radomized controlled trial of desmo- pressin plus terlipressin vs. terlipressin alone for the tre- atment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endosco- pic Club // Hepatology. 1993. Vol. 18. P. 1102–1107.
20. Francis J.L., Armstrong D.J. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease // Haemostasis. 1982. Vol. 11. P. 215–222.
21. Garrison R.N., Cryer H.M., Howard D.A., Polk H.C.Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis // Ann. Surg. 1984. Vol. 199. P. 648–655.
22. Grant A., Neuberger J. Guidelines on the use of liver biopsy in clinical practice // British Society of Gastroen- terology. Gut. 1999. Vol. 45 Suppl. 4. P. IV1–IV11.
23. Hersch S.L., Kunelis T., Francis R.B.Jr. The pathogene- sis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor // Blood. 1987. Vol. 69. P. 1315–1319.
24. Hou M.C. et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemor-
25. rhage: a randomized trial // Hepatology. 2004. Vol. 39.P. 746–753.
26. Hutchison D.E. et al. Platelet changes following clinical and experimental hepatic homotransplantation // Arch.
27. Surg. 1968. Vol. 97. P. 27–33.
28. Kamath P.S. et al. A model to predict survival in patients with end-stage liver disease // Hepatology. 2001. Vol. 33.
29. P. 464–470.
30. Kang Y.G. et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver trans-
31. plantation // Anesth. Analg. 1985. Vol. 64. P. 888–896.
32. Kang Y.G. et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation // Anesthesio-
33. logy. 1987. Vol. 66. P. 766–773.
34. Kerr R. et al. Effects of acute liver injury on blood coagulation // J. Thromb Haemost. 2003. Vol. 1. P. 754–759.
35. Kerr R. New insights into haemostasis in liver failure // Blood Coagul. Fibrinolysis. 2003. Vol. 14. (Suppl 1).
36. P. S43–S45.
37. Jeffers L. et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparo- scopic liver biopsy // Gastroenterology. 2002. Vol. 123. P. 118–126.
38. Mangano D.T., Tudor I.C., Dietzel C. The risk associ- ated with aprotinin in cardiac surgery // N. Engl. J. Med. 2006. Vol. 354. P. 353–365.
39. Mannucci P.M., Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation // Lancet. 1982. Vol. 2. P. 463–467.
40. Meijer K. et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coa- gulation and fibrinolysis // Blood Coagul Fibrinolysis. 2003. Vol. 14. P. 169–174.
41. Moriau M., Kestens P.J., Masure R. Heparin and an- tifibrinolytic agents during experimental hepatectomy and liver transplantation // Pathol Eur. 1969. Vol. 4. P. 172–182.
42. Palomo Sanchez J.C. et al. Effects of intraopera- tive blood transfusion on postoperative complications and survival after orthotopic liver transplantation// Hepatogastroenterology. 1998. Vol. 45. P. 1026–1033.
43. Perkins L., Jeffries M., Patel T. Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis // Clin. Gastroenterol. Hepatol. 2004. Vol. 2. P. 1123–1128.
44. Pernambuco J.R. et al. Activation of the fibrinolytic sys- tem in patients with fulminant liver failure // Hepatol- ogy. 1993. Vol. 18. P. 1350–1356.
45. Salooja N., Perry D.J. Thrombelastography // Blood Co- agul Fibrinolysis. 2001. Vol. 12. P. 327–337.
46. Senzolo M. et al. New insights into the coagulopathy of liver disease and liver transplantation // World J. Gastro- enterol. 2006. Vol. 12 (48). P. 7725–7736.
47. Shore-Lesserson L. Point-of-care coagulation monitor- ing for cardiovascular patients: past and present // J. Car- diothorac. Vasc. Anesth. 2002. Vol. 16. P. 99–106.
48. Steib A. et al. Intraoperative blood losses and transfu- sion requirements during adult liver transplantation re- main difficult to predict // Can J. Anaesth. 2001. Vol. 48. P. 1075–1079.
49. Thalheimer U. et al. Endogenous heparinoids in acute variceal bleeding // Gut. 2005. Vol. 54. P. 310–311.
50. Tripodi A. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests // Hepatology. 2005. Vol. 41. P. 553–558.
51. Violi F. et al. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group // Hepatology. 1995. Vol. 22. P. 96–100.
52. Violi F. et al. Association between high values of D-di- mer and tissue-plasminogen activator activity and first
53. gastrointestinal bleeding in cirrhotic patients // CALC
54. Group. Thromb. Haemost. 1996. Vol. 76. P. 177–183. 47. Wanless I.R. et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension // Hepatology. 1995.
55. Vol. 21. P. 1238–1247.
56. Wong A.Y. et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy // Can J. Anaesth. 2003. Vol. 50. P. 14–20.
Рецензия
Для цитирования:
Минов А.Ф., Дзядзько А.М., Руммо О.О. НАРУШЕНИЯ ГЕМОСТАЗА ПРИ ЗАБОЛЕВАНИЯХ ПЕЧЕНИ. Вестник трансплантологии и искусственных органов. 2010;12(2):82-91. https://doi.org/10.15825/1995-1191-2010-2-82-91
For citation:
Minov A.F., Dzyadzko A.M., Rummo O.O. HEMOSTATIC DISORDERS IN LIVER DISEASES. Russian Journal of Transplantology and Artificial Organs. 2010;12(2):82-91. (In Russ.) https://doi.org/10.15825/1995-1191-2010-2-82-91